James Cleary, MD, PhD
Dana-Farber Cancer Institute · Dana Farber Cancer Instiute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name James Cleary, MD, PhD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 13:34 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT05419479 · Switch Maintenance in PancreaticJames Cleary, MD, PhD · suspended · Pancreatic Cancer, Adenocarcinoma of the Pancreas, Squamous Cell Carcinoma of Pancreas · principal investigator
- Ph2NCT05212025 · Adavosertib and Gemcitabine in Advanced PancreaticJames Cleary, MD, PhD · withdrawn · Pancreatic Cancer · principal investigator
- Ph2NCT03601923 · Niraparib in Patients With Pancreatic CancerDana-Farber Cancer Institute · completed · Pancreatic Cancer · principal investigator
- Ph2NCT02919969 · Pembrolizumab in Metastatic Anal CancerDana-Farber Cancer Institute · completed · Anal Cancer · principal investigator
- Ph1NCT02133625 · A Study of Pioglitazone and Carboplatin in Patients With Advanced Solid TumorsDana-Farber Cancer Institute · completed · Advanced Solid Tumor, Metastatic Solid Tumor · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 13:34 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in pancreatic cancer.